Strategies aiming to modify the composition of the gut microbiome in an anti-inflammatory manner to enhance metabolite barriers and change the composition of the microbial community will have little net impact on the levels of pro-inflammatory cytokines such as IL-6 and TNF-α, which are known to aggravate depression. The gene discussed is IL6; the disease is depressive disorder.